duvakitug vs tulisokibart

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Ulcerative Colitis

Shared mechanism: TL1A · full Ulcerative Colitis pipeline

duvakitug

Developed by Teva Pharmaceutical Industries and partners

Phase 3 in Ulcerative Colitismonoclonal antibody (IgG1-λ2)
Partial signal

NCT05499130 · Phase 2b · completed

Randomized, double-blind, placebo-controlled dose-ranging basket study in UC and Crohn's disease. In UC the high dose separated from placebo on clinical remission (p=.003) and the low dose was borderline (p=.050); in Crohn's disease endoscopic response was 47.8% (high dose) and 26.1% (low dose) vs 13.0% placebo. The sponsor reports one-sided p-values at a 0.10 significance level, a lenient threshold, and each cohort was modest in size. A well-designed Phase 2b with a dose-dependent, partly borderline result is capped at moderate. Progressed to Phase 3.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: May 2028 · NCT07184996 (registry estimate)

Reported efficacy

Clinical remission (mMS) at week 14: UC cohort, clinical remission at week 14: 36% (450 mg) / 48% (900 mg) vs 20% placebo, placebo-adjusted 16% (p=.050) / 27% (p=.003). CD cohort, endoscopic response: 26.1% (low dose) / 47.8% (high dose) vs 13.0% placebo. P-values are one-sided at a 0.10 significance level. (met)

Result source: NCT05499130

tulisokibart

Developed by Merck & Co.

Phase 3 in Ulcerative Colitismonoclonal antibody (humanized)
Reliable signal

NCT06052059 · Phase 3 · active, not recruiting

First Ph3 induction win for any anti-TL1A; met primary + key secondaries (June 2026).

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: December 2037 · NCT06651281 (registry estimate)

Reported efficacy

Clinical remission (MMS) at week 12: ATLAS-UC Study 2 (NCT06052059): tulisokibart met its primary endpoint of clinical remission (Modified Mayo Score) at week 12, plus key secondary endpoints. (met)

Result source: NCT06052059

Results for Ulcerative Colitis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointduvakitugtulisokibart
Clinical remission (induction)47.8% vs 20.5%+27.3 vs placebo900 mg · wk 14 · n 46NCT05499130
3 other results
  • 36.2% vs 20.5% 450 mg · wk 14 · n 47 · Phase 2b · primary NCT05499130
  • 23.9% vs 9.1% 900 mg · wk 14 · n 46 · Phase 2b · secondary NCT05499130
  • 29.8% vs 9.1% 450 mg · wk 14 · n 47 · Phase 2b · secondary NCT05499130
26.5% vs 1.5%+25 vs placebowk 12 · n 68NCT04996797
1 other result
  • 31.6% vs 10.8% wk 12 · n 38 · Phase 2 · secondary NCT04996797
Clinical remission (maintenance)—Trial running · NCT07185009—Trial running · NCT06052059
Clinical response (induction)69.6% vs 52.3%+17.3 vs placebo900 mg · wk 14 · n 46NCT05499130
3 other results
  • 73.9% vs 50% 900 mg · wk 14 · n 46 · Phase 2b · secondary NCT05499130
  • 80.9% vs 52.3% 450 mg · wk 14 · n 47 · Phase 2b · secondary NCT05499130
  • 83% vs 50% 450 mg · wk 14 · n 47 · Phase 2b · secondary NCT05499130
66.2% vs 22.4%+43.8 vs placebowk 12 · n 68NCT04996797
1 other result
  • 55.3% vs 32.4% wk 12 · n 38 · Phase 2 · secondary NCT04996797
Endoscopic improvement (induction)—Trial running · NCT0718500936.8% vs 6%+30.8 vs placebowk 12 · n 68NCT04996797
1 other result
  • 36.8% vs 18.9% wk 12 · n 38 · Phase 2 · secondary NCT04996797
Corticosteroid-free remission (maintenance)—Trial running · NCT07185009—Trial running · NCT06052059

Clinical remission (induction)

duvakitug
47.8% vs 20.5%+27.3 vs placebo900 mg · wk 14 · n 46NCT05499130
3 other results
  • 36.2% vs 20.5% 450 mg · wk 14 · n 47 · Phase 2b · primary NCT05499130
  • 23.9% vs 9.1% 900 mg · wk 14 · n 46 · Phase 2b · secondary NCT05499130
  • 29.8% vs 9.1% 450 mg · wk 14 · n 47 · Phase 2b · secondary NCT05499130
tulisokibart
26.5% vs 1.5%+25 vs placebowk 12 · n 68NCT04996797
1 other result
  • 31.6% vs 10.8% wk 12 · n 38 · Phase 2 · secondary NCT04996797

Clinical remission (maintenance)

duvakitug
—Trial running · NCT07185009
tulisokibart
—Trial running · NCT06052059

Clinical response (induction)

duvakitug
69.6% vs 52.3%+17.3 vs placebo900 mg · wk 14 · n 46NCT05499130
3 other results
  • 73.9% vs 50% 900 mg · wk 14 · n 46 · Phase 2b · secondary NCT05499130
  • 80.9% vs 52.3% 450 mg · wk 14 · n 47 · Phase 2b · secondary NCT05499130
  • 83% vs 50% 450 mg · wk 14 · n 47 · Phase 2b · secondary NCT05499130
tulisokibart
66.2% vs 22.4%+43.8 vs placebowk 12 · n 68NCT04996797
1 other result
  • 55.3% vs 32.4% wk 12 · n 38 · Phase 2 · secondary NCT04996797

Endoscopic improvement (induction)

duvakitug
—Trial running · NCT07185009
tulisokibart
36.8% vs 6%+30.8 vs placebowk 12 · n 68NCT04996797
1 other result
  • 36.8% vs 18.9% wk 12 · n 38 · Phase 2 · secondary NCT04996797

Corticosteroid-free remission (maintenance)

duvakitug
—Trial running · NCT07185009
tulisokibart
—Trial running · NCT06052059
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. duvakitug: 4 of 4 rows · tulisokibart: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricduvakitugtulisokibart
Dropout rate
0%1800 mga
NCT05499130 · Phase 2b · monotherapy
show 5 more results
0%1800 mg
NCT05499130 · Phase 2b · monotherapy
8.5%900 mg
NCT05499130 · Phase 2b · monotherapy
2.2%900 mg
NCT05499130 · Phase 2b · monotherapy
19.6%450 mg
NCT05499130 · Phase 2b · monotherapy
0%450 mg
NCT05499130 · Phase 2b · monotherapy
—All Cohorts (Cohort 1 & Cohort 2)
NCT04996797 · Phase 2 · Ulcerative Colitis · phase 2
show 1 more result
n/a: no completion milestoneCohort 1 Tulisokibart
NCT04996797 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2
Discontinued due to AEs
0%1800 mga
NCT05499130 · Phase 2b · monotherapy
show 5 more results
0%1800 mg
NCT05499130 · Phase 2b · monotherapy
2.1%900 mg
NCT05499130 · Phase 2b · monotherapy
2.2%900 mg
NCT05499130 · Phase 2b · monotherapy
8.7%450 mg
NCT05499130 · Phase 2b · monotherapy
0%450 mg
NCT05499130 · Phase 2b · monotherapy
—All Cohorts (Cohort 1 & Cohort 2)
NCT04996797 · Phase 2 · Ulcerative Colitis · phase 2
show 1 more result
0%Cohort 1 Tulisokibart
NCT04996797 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2
Serious AEs
0%1800 mga
NCT05499130 · Phase 2b · monotherapy
show 5 more results
0%1800 mg
NCT05499130 · Phase 2b · monotherapy
2.2%900 mg
NCT05499130 · Phase 2b · monotherapy
2.2%900 mg
NCT05499130 · Phase 2b · monotherapy
13%450 mg
NCT05499130 · Phase 2b · monotherapy
0%450 mg
NCT05499130 · Phase 2b · monotherapy
1.1%All Cohorts (Cohort 1 & Cohort 2)
NCT04996797 · Phase 2 · Ulcerative Colitis · phase 2
show 1 more result
—Cohort 1 Tulisokibart
NCT04996797 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2
Most frequent reported AEs
1800 mga
eczema 33.3% (placebo 0%)
influenza 33.3% (placebo 2.2%)
proteinuria 33.3% (placebo 0%)
NCT05499130 · Phase 2b · monotherapy
show 5 more results
1800 mg
abnormal uterine bleeding 14.3% (placebo 0%)
insomnia 14.3% (placebo 0%)
anaemia 0% (placebo 2.2%)
NCT05499130 · Phase 2b · monotherapy
900 mg
nasopharyngitis 6.5% (placebo 6.5%)
headache 2.2% (placebo 2.2%)
vomiting 2.2% (placebo 4.3%)
NCT05499130 · Phase 2b · monotherapy
900 mg
headache 4.3% (placebo 2.2%)
influenza 4.3% (placebo 2.2%)
anaemia 2.2% (placebo 2.2%)
NCT05499130 · Phase 2b · monotherapy
450 mg
headache 8.7% (placebo 2.2%)
anaemia 6.5% (placebo 2.2%)
nasopharyngitis 4.3% (placebo 6.5%)
NCT05499130 · Phase 2b · monotherapy
450 mg
nasopharyngitis 6.4% (placebo 6.5%)
upper respiratory tract infection 6.4% (placebo 4.3%)
vomiting 6.4% (placebo 4.3%)
NCT05499130 · Phase 2b · monotherapy
covid-19 5.6% (placebo 4.5%)
NCT04996797 · Phase 2 · Ulcerative Colitis · phase 2

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

duvakitug

Endoscopic Improvement 50% (n=46) vs 22.7% (n=44) placebo @ 14wk900 mg
event count · % of participants
NCT05499130 · Phase 2b · monotherapy · converted to % from 23 Participants as posted
show 1 more result
44.7% (n=47) vs 22.7% (n=44) placebo @ 14wk*450 mg
NCT05499130 · Phase 2b · monotherapy · converted to % from 21 Participants as posted
Endoscopic Remission 17.4% (n=46) vs 6.8% (n=44) placebo @ 14wk900 mg
responder rate · % of participants
NCT05499130 · Phase 2b · monotherapy · converted to % from 8 Participants as posted
show 1 more result
17% (n=47) vs 6.8% (n=44) placebo @ 14wk*450 mg
NCT05499130 · Phase 2b · monotherapy · converted to % from 8 Participants as posted

tulisokibart

Endoscopic Improvement 36.8% (n=68) vs 6% (n=67) placebo @ 12wk
responder rate · % of participants
NCT04996797 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2
show 1 more result
36.8% (n=38) vs 18.9% (n=37) placebo @ 12wk
NCT04996797 · Phase 2 · combination · Ulcerative Colitis · phase 2
Symptomatic Remission 19.1% (n=68) vs 6% (n=67) placebo @ 12wk
responder rate · % of participants
NCT04996797 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2
show 1 more result
21.1% (n=38) vs 10.8% (n=37) placebo @ 12wk
NCT04996797 · Phase 2 · combination · Ulcerative Colitis · phase 2
Histologic Improvement 46.2% (n=65) vs 17.5% (n=57) placebo @ 12wk
responder rate · % of participants
NCT04996797 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2
show 1 more result
55.6% (n=36) vs 26.7% (n=30) placebo @ 12wk
NCT04996797 · Phase 2 · combination · Ulcerative Colitis · phase 2
Histologic-Endoscopic Mucosal Improvement 30.8% (n=65) vs 3.5% (n=57) placebo @ 12wk
responder rate · % of participants
NCT04996797 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2
show 1 more result
38.9% (n=36) vs 16.7% (n=30) placebo @ 12wk
NCT04996797 · Phase 2 · combination · Ulcerative Colitis · phase 2
Histologic-endoscopic Mucosal Healing 30.8% (n=65) vs 3.5% (n=57) placebo @ 12wk
responder rate · % of participants
NCT04996797 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2
show 1 more result
38.9% (n=36) vs 16.7% (n=30) placebo @ 12wk
NCT04996797 · Phase 2 · combination · Ulcerative Colitis · phase 2
IBDQ 82.4% (n=68) vs 49.3% (n=67) placebo @ 12wk
responder rate · % of participants
NCT04996797 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2
show 1 more result
76.3% (n=38) vs 56.8% (n=37) placebo @ 12wk
NCT04996797 · Phase 2 · combination · Ulcerative Colitis · phase 2

Crohn's Disease

Shared mechanism: TL1A · full Crohn's Disease pipeline

duvakitug

Developed by Teva Pharmaceutical Industries and partners

Phase 3 in Crohn's Diseasemonoclonal antibody (IgG1-λ2)
Partial signal

NCT05499130 · Phase 2b · completed

Randomized, double-blind, placebo-controlled dose-ranging basket study in UC and Crohn's disease. In UC the high dose separated from placebo on clinical remission (p=.003) and the low dose was borderline (p=.050); in Crohn's disease endoscopic response was 47.8% (high dose) and 26.1% (low dose) vs 13.0% placebo. The sponsor reports one-sided p-values at a 0.10 significance level, a lenient threshold, and each cohort was modest in size. A well-designed Phase 2b with a dose-dependent, partly borderline result is capped at moderate. Progressed to Phase 3.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: August 2028 · NCT07923383 (registry estimate)

Reported efficacy

Clinical remission (mMS) at week 14: UC cohort, clinical remission at week 14: 36% (450 mg) / 48% (900 mg) vs 20% placebo, placebo-adjusted 16% (p=.050) / 27% (p=.003). CD cohort, endoscopic response: 26.1% (low dose) / 47.8% (high dose) vs 13.0% placebo. P-values are one-sided at a 0.10 significance level. (met)

Result source: NCT05499130

tulisokibart

Developed by Merck & Co.

Phase 3 in Crohn's Diseasemonoclonal antibody (humanized)
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: October 2028 · NCT06430801 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Crohn's Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointduvakitugtulisokibart
Clinical remission (induction)54.3% vs 41.3%+13 vs placebo900 mg · wk 14 · n 46NCT05499130
3 other results
  • 37% vs 26.1% 900 mg · wk 14 · n 46 · Phase 2b · secondary NCT05499130
  • 50% vs 41.3% 450 mg · wk 14 · n 46 · Phase 2b · secondary NCT05499130
  • 37% vs 26.1% 450 mg · wk 14 · n 46 · Phase 2b · secondary NCT05499130
—Trial running · NCT06651281
Endoscopic response (induction)47.8% vs 13%+34.8 vs placebo900 mg · wk 14 · n 46NCT05499130
3 other results
  • 26.1% vs 13% 450 mg · wk 14 · n 46 · Phase 2b · primary NCT05499130
  • 39.1% vs 13% 900 mg · wk 14 · n 46 · Phase 2b · secondary NCT05499130
  • 34.8% vs 13% 450 mg · wk 14 · n 46 · Phase 2b · secondary NCT05499130
—Trial running · NCT06651281
Clinical remission (maintenance)—Trial running · NCT07184944—Trial running · NCT06651281
Endoscopic response (maintenance)—Trial running · NCT07184944—Trial running · NCT06651281

Clinical remission (induction)

duvakitug
54.3% vs 41.3%+13 vs placebo900 mg · wk 14 · n 46NCT05499130
3 other results
  • 37% vs 26.1% 900 mg · wk 14 · n 46 · Phase 2b · secondary NCT05499130
  • 50% vs 41.3% 450 mg · wk 14 · n 46 · Phase 2b · secondary NCT05499130
  • 37% vs 26.1% 450 mg · wk 14 · n 46 · Phase 2b · secondary NCT05499130
tulisokibart
—Trial running · NCT06651281

Endoscopic response (induction)

duvakitug
47.8% vs 13%+34.8 vs placebo900 mg · wk 14 · n 46NCT05499130
3 other results
  • 26.1% vs 13% 450 mg · wk 14 · n 46 · Phase 2b · primary NCT05499130
  • 39.1% vs 13% 900 mg · wk 14 · n 46 · Phase 2b · secondary NCT05499130
  • 34.8% vs 13% 450 mg · wk 14 · n 46 · Phase 2b · secondary NCT05499130
tulisokibart
—Trial running · NCT06651281

Clinical remission (maintenance)

duvakitug
—Trial running · NCT07184944
tulisokibart
—Trial running · NCT06651281

Endoscopic response (maintenance)

duvakitug
—Trial running · NCT07184944
tulisokibart
—Trial running · NCT06651281
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. duvakitug: 4 of 4 rows · tulisokibart: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricduvakitugtulisokibart
Dropout rate
0%1800 mga
NCT05499130 · Phase 2b · monotherapy
show 5 more results
0%1800 mg
NCT05499130 · Phase 2b · monotherapy
8.5%900 mg
NCT05499130 · Phase 2b · monotherapy
2.2%900 mg
NCT05499130 · Phase 2b · monotherapy
19.6%450 mg
NCT05499130 · Phase 2b · monotherapy
0%450 mg
NCT05499130 · Phase 2b · monotherapy
—250 mga
NCT05013905 · Phase 2 · registry result, not featured evidence
show 2 more results
—100 mg
NCT05013905 · Phase 2 · registry result, not featured evidence
10.9%Induction Tulisokibart
NCT05013905 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
0%1800 mga
NCT05499130 · Phase 2b · monotherapy
show 5 more results
0%1800 mg
NCT05499130 · Phase 2b · monotherapy
2.1%900 mg
NCT05499130 · Phase 2b · monotherapy
2.2%900 mg
NCT05499130 · Phase 2b · monotherapy
8.7%450 mg
NCT05499130 · Phase 2b · monotherapy
0%450 mg
NCT05499130 · Phase 2b · monotherapy
—250 mga
NCT05013905 · Phase 2 · registry result, not featured evidence
show 2 more results
—100 mg
NCT05013905 · Phase 2 · registry result, not featured evidence
—Induction Tulisokibart
NCT05013905 · Phase 2 · registry result, not featured evidence
Serious AEs
0%1800 mga
NCT05499130 · Phase 2b · monotherapy
show 5 more results
0%1800 mg
NCT05499130 · Phase 2b · monotherapy
2.2%900 mg
NCT05499130 · Phase 2b · monotherapy
2.2%900 mg
NCT05499130 · Phase 2b · monotherapy
13%450 mg
NCT05499130 · Phase 2b · monotherapy
0%450 mg
NCT05499130 · Phase 2b · monotherapy
22.2%250 mga
NCT05013905 · Phase 2 · registry result, not featured evidence
show 2 more results
21.1%100 mg
NCT05013905 · Phase 2 · registry result, not featured evidence
16.4%Induction Tulisokibart
NCT05013905 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
1800 mga
eczema 33.3% (placebo 0%)
influenza 33.3% (placebo 2.2%)
proteinuria 33.3% (placebo 0%)
NCT05499130 · Phase 2b · monotherapy
show 5 more results
1800 mg
abnormal uterine bleeding 14.3% (placebo 0%)
insomnia 14.3% (placebo 0%)
anaemia 0% (placebo 2.2%)
NCT05499130 · Phase 2b · monotherapy
900 mg
nasopharyngitis 6.5% (placebo 6.5%)
headache 2.2% (placebo 2.2%)
vomiting 2.2% (placebo 4.3%)
NCT05499130 · Phase 2b · monotherapy
900 mg
headache 4.3% (placebo 2.2%)
influenza 4.3% (placebo 2.2%)
anaemia 2.2% (placebo 2.2%)
NCT05499130 · Phase 2b · monotherapy
450 mg
headache 8.7% (placebo 2.2%)
anaemia 6.5% (placebo 2.2%)
nasopharyngitis 4.3% (placebo 6.5%)
NCT05499130 · Phase 2b · monotherapy
450 mg
nasopharyngitis 6.4% (placebo 6.5%)
upper respiratory tract infection 6.4% (placebo 4.3%)
vomiting 6.4% (placebo 4.3%)
NCT05499130 · Phase 2b · monotherapy
250 mga
crohn's disease 33.3%
gastroenteritis 22.2%
upper respiratory tract infection 16.7%
NCT05013905 · Phase 2 · registry result, not featured evidence
show 2 more results
100 mg
crohn's disease 36.8%
upper respiratory tract infection 26.3%
covid-19 15.8%
NCT05013905 · Phase 2 · registry result, not featured evidence
covid-19 12.7%
urinary tract infection 9.1%
anaemia 7.3%
NCT05013905 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

duvakitug

Endoscopic 47.8% (n=46) vs 13% (n=46) placebo @ 14wk900 mg
responder rate · % of participants
NCT05499130 · Phase 2b · monotherapy · converted to % from 22 Participants as posted
show 3 more results
39.1% (n=46) vs 13% (n=46) placebo @ 14wk*900 mg
NCT05499130 · Phase 2b · monotherapy · converted to % from 18 Participants as posted
26.1% (n=46) vs 13% (n=46) placebo @ 14wk*450 mg
NCT05499130 · Phase 2b · monotherapy · converted to % from 12 Participants as posted
34.8% (n=46) vs 13% (n=46) placebo @ 14wk*450 mg
NCT05499130 · Phase 2b · monotherapy · converted to % from 16 Participants as posted
Clinical Response 39.1% (n=46) vs 32.6% (n=46) placebo @ 4wk900 mg
responder rate · % of participants
NCT05499130 · Phase 2b · monotherapy · converted to % from 18 Participants as posted
show 9 more results
54.3% (n=46) vs 41.3% (n=46) placebo @ 8wk*900 mg
NCT05499130 · Phase 2b · monotherapy · converted to % from 25 Participants as posted
67.4% (n=46) vs 47.8% (n=46) placebo @ 12wk*900 mg
NCT05499130 · Phase 2b · monotherapy · converted to % from 31 Participants as posted
65.2% (n=46) vs 52.2% (n=46) placebo @ 14wk*900 mg
NCT05499130 · Phase 2b · monotherapy · converted to % from 30 Participants as posted
30.4% (n=46) vs 17.4% (n=46) placebo @ 14wk*900 mg
NCT05499130 · Phase 2b · monotherapy · converted to % from 14 Participants as posted
52.2% (n=46) vs 32.6% (n=46) placebo @ 4wk*450 mg
NCT05499130 · Phase 2b · monotherapy · converted to % from 24 Participants as posted
65.2% (n=46) vs 41.3% (n=46) placebo @ 8wk*450 mg
NCT05499130 · Phase 2b · monotherapy · converted to % from 30 Participants as posted
67.4% (n=46) vs 47.8% (n=46) placebo @ 12wk*450 mg
NCT05499130 · Phase 2b · monotherapy · converted to % from 31 Participants as posted
65.2% (n=46) vs 52.2% (n=46) placebo @ 14wk*450 mg
NCT05499130 · Phase 2b · monotherapy · converted to % from 30 Participants as posted
34.8% (n=46) vs 17.4% (n=46) placebo @ 14wk*450 mg
NCT05499130 · Phase 2b · monotherapy · converted to % from 16 Participants as posted
Clinical Remission 54.3% (n=46) vs 41.3% (n=46) placebo @ 14wk900 mg
responder rate · % of participants
NCT05499130 · Phase 2b · monotherapy · converted to % from 25 Participants as posted
show 3 more results
37% (n=46) vs 26.1% (n=46) placebo @ 14wk*900 mg
NCT05499130 · Phase 2b · monotherapy · converted to % from 17 Participants as posted
50% (n=46) vs 41.3% (n=46) placebo @ 14wk*450 mg
NCT05499130 · Phase 2b · monotherapy · converted to % from 23 Participants as posted
37% (n=46) vs 26.1% (n=46) placebo @ 14wk*450 mg
NCT05499130 · Phase 2b · monotherapy · converted to % from 17 Participants as posted

tulisokibart

Endoscopic Improvement 26% (n=50) @ 12wk
event count · % of participants
No placebo or comparator arm
NCT05013905 · Phase 2 · registry result, not featured evidence · converted to % from 13 Participants as posted
Clinical Remission 49.1% (n=55) @ 12wk
responder rate · % of participants
No placebo or comparator arm
NCT05013905 · Phase 2 · registry result, not featured evidence · converted to % from 27 Participants as posted
Clinical Response and Endoscopic 16.4% (n=55) @ 12wk
responder rate · % of participants
No placebo or comparator arm
NCT05013905 · Phase 2 · registry result, not featured evidence · converted to % from 9 Participants as posted
Clinical-Biomarker 34.7% (n=49) @ 12wk
responder rate · % of participants
No placebo or comparator arm
NCT05013905 · Phase 2 · registry result, not featured evidence · converted to % from 17 Participants as posted
Clinical Response 67.3% (n=55) @ 12wk
responder rate · % of participants
No placebo or comparator arm
NCT05013905 · Phase 2 · registry result, not featured evidence · converted to % from 37 Participants as posted
PRO-2 Remission 49.1% (n=55) @ 12wk
responder rate · % of participants
No placebo or comparator arm
NCT05013905 · Phase 2 · registry result, not featured evidence · converted to % from 27 Participants as posted
SES-CD -2.6 score @ 12wk
absolute change · score
No placebo or comparator arm
NCT05013905 · Phase 2 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: duvakitug's landscape · tulisokibart's landscape